# Kevin L. Duffin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kevin-l-duffin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,651 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 52 |
| i10-index | 99 |
| Last Known Institution | Eli Lilly (United States) |
| OpenAlex ID | https://openalex.org/A5072130761 |
| ORCID iD | 0000-0002-1656-8982 |
| Works | 201 |

## Researcher papers

- [Guanylin: an endogenous activator of intestinal guanylate cyclase.](https://scholariq.org/papers/guanylin-an-endogenous-activator-of-intestinal-guanylate-cyclase/)
- [A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes](https://scholariq.org/papers/a-signature-of-circulating-inflammatory-proteins-and-development-of-end-stage/)
- [Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis](https://scholariq.org/papers/diagnostic-accuracy-of-elastography-and-magnetic-resonance-imaging-in-patients/)
- [Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes](https://scholariq.org/papers/effects-of-novel-dual-gip-and-glp-1-receptor-agonist-tirzepatide-on-biomarkers/)
- [Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes](https://scholariq.org/papers/dual-gip-and-glp-1-receptor-agonist-tirzepatide-improves-beta-cell-function-and/)
- [Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway.](https://scholariq.org/papers/order-and-specificity-of-the-plasmodium-falciparum-hemoglobin-degradation/)
- [Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial](https://scholariq.org/papers/effects-of-tirzepatide-versus-insulin-glargine-on-kidney-outcomes-in-type-2/)
- [JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial](https://scholariq.org/papers/jak1-jak2-inhibition-by-baricitinib-in-diabetic-kidney-disease-results-from-a/)
- [Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis](https://scholariq.org/papers/enhanced-liver-fibrosis-test-for-the-non-invasive-diagnosis-of-fibrosis-in/)
- [Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy](https://scholariq.org/papers/anti-tgf-1-antibody-therapy-in-patients-with-diabetic-nephropathy/)
- [Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide](https://scholariq.org/papers/indicators-of-kidney-fibrosis-in-patients-with-type-2-diabetes-and-chronic/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Spectroscopy and Laser Applications](https://scholariq.org/topics/spectroscopy-and-laser-applications/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Laser Design and Applications](https://scholariq.org/topics/laser-design-and-applications/)

## Researcher university

- [Eli Lilly (United States)](https://scholariq.org/institutions/eli-lilly-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.